摘要
目的 评价微粒子捕捉酶免疫法检测糖链抗原 19 9(CA19 9)的临床应用价值。方法 运用微粒子捕捉酶免疫方法检测胃癌、肝癌、胰腺癌及胰腺炎、良性胃疾病患者和健康人的血清CA19 9水平。结果 胃癌、肝癌、胰腺癌患者的CA19 9水平较健康人显著升高 ,对胰腺癌及胃癌的正确诊断率分别为 89.8%及 93.4%。结论 CA19 9是诊断胰腺癌及胃癌的最为有效的肿瘤标志物之一 ,运用微粒子捕捉免疫技术进行检测可提高临床诊断水平。
Objective To evaluate the clinical significance of the detection of carbohydrate antigen 19 9(CA19 9) by microparticle enzyme immunoassay (MEIA).Methods The serum levels of CA19 9 were assayed by MEIA in 45 gastric cancer patients,36 liver cancer patients,12 pancreatoncus patients,as well as healthy group.Results The levels of CA19 9 in groups of gastric cancer,liver cancer and pancreatoncus were significantly higher than that in healthy group.The rate of diagnostic coincidence was 89..8% in pancreatoncus and 93.4% in gastric cancer.Conclusion CA19 9 is one of the most effective tumor markers in diagnosing gastric cancer and pancreatoncus.The clinical diagnostic level can be improved by using MEIA.
出处
《河北医药》
CAS
2001年第10期725-726,共2页
Hebei Medical Journal
基金
河北省卫生厅资助项目 编号 980 0 2 1 1